Differential expression of gene profiling in therapeutic response and non-response cervical carcinoma

Abstract

Cervical carcinoma is one of the most common malignancies in women worldwide. Persistent infection with high risk human papillomavirus is the most significant factor for carcinogenesis of cervical cancer. Therapeutic modalities of cervical carcinoma are not efficiently controlling the progression of cancer in one third of patients. Therefore, understanding of molecular mechanisms in cancer progression is important to prevent disease progression and improve treatment efficacy leading to the reduction of incidence and mortality rate. We investigated genes differentially expressed in therapeutic response and non–response cervical carcinoma stage IIIB using the human whole genome microarrays. The differential expression of genes in each group was constructed for the network by IPA software. Differentially expressed genes in non–responses compared with responses were identified, which were 167 up-regulated and 146 down-regulated genes. The up-regulated genes have biological functions involved in signal transduction (CXCL10, ERBB2, TRAF5, FPRL1, IL1B, FGFBP1 and SCTR), cell proliferation (REG1A, AREG, TGFBI, ERBB2, PIM2, EIF5A and ISG20), proteolysis (PLAU, CRADD, C1R, KLK14, TMEM27, ICEBERG, BF and ADAMTS8), and cell migration (ERBB2, IL8, IL1B, and FPRL1). The down-regulated genes have biological functions involved in transcription (GLIS1, ZNF337, SOX4, PITX1, LASS4, GRHL3, CRABP2, SUHW3, TLE2 and KLF8), cell adhesion (PCDHB6, TRO, MAGI1, PVRL4, SLURP1 and MUC4), and signal transduction (CD38, CXCL14, HTR2B, CEACAM6, DPYSL3, NCR1, CRABP2, CLIC3, TLE2 and PLXNA2). Our study indicates that multiple genes play distinct roles in response or non-response to therapy in cervical carcinoma.